Hyperfine (HYPR)
NASDAQ:HYPR
Top Page
Hyperfine
(NASDAQ:HYPR)
Select Model
Select Model
Rating:62Neutral
Price Target:
$1.00
▼(-19.35% Downside)
Action:ReiteratedDate:03/19/26
The score is driven by strong earnings-call guidance and improving commercialization metrics (higher revenue trajectory and sustained ~50%+ gross margins), supported by positive technical momentum. These positives are tempered by weak financial sustainability today—large net losses, significant cash burn, and a negative earnings-based valuation signal.
Positive Factors
Gross Margin Expansion
Sustained gross margins near or above 50% indicate durable unit economics for the portable MRI platform. Higher gross profit per unit creates room for scaled SG&A and sales investments, making future operating leverage feasible as revenues grow and reducing dependency on margin-reducing pricing.
Negative Factors
Persistent Net Losses & Cash Burn
Large, sustained losses and negative operating/ free cash flow are eroding equity and necessitate external financing. Even with year‑over‑year improvement, burn remains large relative to revenue, meaning the company must hit aggressive commercial targets to avoid repeated dilution or costly debt that constrain long‑term flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Gross Margin Expansion
Sustained gross margins near or above 50% indicate durable unit economics for the portable MRI platform. Higher gross profit per unit creates room for scaled SG&A and sales investments, making future operating leverage feasible as revenues grow and reducing dependency on margin-reducing pricing.
Read all positive factors
Hyperfine (HYPR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$118.53M
Dividend YieldN/A
Average Volume (3M)762.74K
Price to Earnings (P/E)―
Beta (1Y)1.09
Revenue Growth-20.10%
EPS Growth7.87%
CountryUS
Employees111
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.06
Shares Outstanding82,902,420
10 Day Avg. Volume1,646,855
30 Day Avg. Volume762,741
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)2.25
Price to Sales (P/S)6.80
P/FCF Ratio-3.17
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue4.97
Enterprise Value/Gross Profit9.97
Enterprise Value/Ebitda-1.81
Forecast
1Y Price Target
$2.05Price Target Upside65.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.35
Revenue Forecast (FY)$18.00M
Hyperfine Business Overview & Revenue Model
Company Description
Hyperfine, Inc. provides imaging, monitoring, and magnetic resonance imaging products. It offers Swoop Portable MR imaging system to address an unmet need in point-of-care medical imaging through a combination of hardware and software services. Th...
How the Company Makes Money
Hyperfine primarily makes money by selling its portable MRI systems (capital equipment) to healthcare providers such as hospitals and clinical sites. In addition to system sales, the company generates revenue from recurring and/or ongoing sources ...
Hyperfine Earnings Call Summary
Earnings Call Date:Mar 18, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Positive
The call conveyed meaningful commercial and operational progress: a breakout Q4 with strong unit sales and 128% Q4 revenue growth, sustained gross margin expansion above 50%, reduced cash burn, robust clinical and health-economic validation, and strengthened financing that extends runway into 2028. Counterbalancing these positives are a modest full-year revenue increase (5%), continued net losses, dependence on larger multi-hospital/IDN deals that can create quarter-to-quarter lumpiness, some accounting-driven service revenue variability, and phased international rollouts that delay certain revenue streams. Overall the company appears to be transitioning successfully from development to commercial scale but still faces execution and timing risks tied to larger deals and international expansion.Positive Updates
Strong Q4 Revenue and Unit Growth
Q4 revenue of $5.3M, up 128% vs. $2.3M in Q4 2024; 16 units sold in Q4 2025 vs. 9 units in Q4 2024; second-half 2025 revenue $8.7M vs. $4.8M in first half.
Negative Updates
Modest Full-Year Revenue Growth
Full-year 2025 revenue $13.6M, up only 5% vs. $12.9M in 2024 despite strong Q4; company notes 2025 was a tale of two halves with concentration of growth in H2.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong Q4 Revenue and Unit Growth
Q4 revenue of $5.3M, up 128% vs. $2.3M in Q4 2024; 16 units sold in Q4 2025 vs. 9 units in Q4 2024; second-half 2025 revenue $8.7M vs. $4.8M in first half.
Read all positive updates
Company Guidance
Management guided 2026 revenue of $20–22 million (midpoint ≈ +55% YoY), gross margin of 50–55% with second‑half margins expected to exceed first‑half, and total cash burn of $26–28 million (midpoint ≈ 10% decline YoY) that incorporates estimated quarterly interest payments of ~ $400k; they reported $35.1 million in cash as of 12/31/25, raised > $20M of equity in October and have received a $15M initial tranche (of a potential up to $40M) debt facility with up to $25M additional tranches available through 2027, which management says extends runway into 2028. The guide assumes progressive quarterly revenue strength as multi‑hospital/IDN deals and an international next‑generation Swoop launch ramp in H2, and reflects recent momentum (Q4 revenue $5.3M, +128% YoY; 16 net units sold vs. 9 a year ago; Q4 gross margin 50.9%, +1,530 bps YoY) and improved cash burn trends (net cash burn excl. financing Q4 $5.7M, −30% YoY; FY2025 $29.9M, −22% YoY); device MSRP noted at $590,000.Hyperfine Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 13.56M | 12.89M | 11.03M | 6.81M | 1.50M |
| Gross Profit | 6.75M | 5.89M | 4.76M | 907.00K | -1.17M |
| EBITDA | -34.88M | -42.22M | -47.06M | -72.86M | -64.14M |
| Net Income | -35.57M | -40.72M | -44.24M | -73.16M | -64.83M |
Balance Sheet | |||||
| Total Assets | 55.26M | 58.90M | 94.20M | 134.05M | 202.47M |
| Cash, Cash Equivalents and Short-Term Investments | 35.09M | 37.65M | 75.18M | 118.24M | 188.50M |
| Total Debt | 314.00K | 269.00K | 185.00K | 0.00 | 0.00 |
| Total Liabilities | 14.26M | 9.86M | 9.80M | 10.33M | 16.25M |
| Stockholders Equity | 41.01M | 49.04M | 84.40M | 123.72M | 186.23M |
Cash Flow | |||||
| Free Cash Flow | -29.13M | -39.15M | -42.61M | -72.92M | -49.89M |
| Operating Cash Flow | -27.95M | -38.77M | -41.81M | -72.34M | -47.18M |
| Investing Cash Flow | -1.19M | -383.00K | -804.00K | -585.00K | -2.71M |
| Financing Cash Flow | 27.50M | 1.02M | 174.00K | 7.00K | 176.77M |
Hyperfine Technical Analysis
Positive
1.24
Price Trends
1.14
Positive
1.10
Positive
1.16
Positive
Market Momentum
0.01
Negative
59.72
Neutral
90.39
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYPR, the sentiment is Positive. The current price of 1.24 is above the 20-day moving average (MA) of 1.17, above the 50-day MA of 1.14, and above the 200-day MA of 1.16, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 59.72 is Neutral, neither overbought nor oversold. The STOCH value of 90.39 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HYPR.
Hyperfine Risk Analysis
Hyperfine disclosed 79 risk factors in its most recent earnings report. Hyperfine reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Hyperfine Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $117.30M | 14.16 | 4.34% | ― | 3.36% | -21.15% | |
62 Neutral | $118.53M | -2.59 | -103.93% | ― | -20.10% | 7.87% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $22.21M | ― | -221.04% | ― | -18.96% | 8.98% | |
43 Neutral | $12.67M | -1.57 | -335.47% | ― | 18.76% | 60.09% | |
39 Underperform | $4.99M | -0.35 | -247.60% | ― | ― | 15.03% |
* Healthcare Sector Average
HYPR
Hyperfine
1.25
0.55
78.83%
FONR
Fonar
18.76
6.62
54.53%
MODD
Modular Medical
4.81
-21.59
-81.78%
RBOT
Vicarious Surgical
0.70
-5.04
-87.80%
VVOS
Vivos Therapeutics
1.35
-0.84
-38.36%
ICCM
Icecure Medical
0.35
-0.75
-67.82%
Hyperfine Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Hyperfine Secures $40 Million Term Loan Financing Agreement
Positive
Mar 18, 2026
On March 18, 2026, Hyperfine, Inc. entered into a Loan and Security Agreement with Horizon Technology Finance Corporation for a senior secured term loan facility of up to $40 million, of which $15 million was drawn at closing for working capital a...
Business Operations and StrategyFinancial Disclosures
Hyperfine Announces Strong Preliminary Q4 2025 Revenue Growth
Positive
Jan 12, 2026
On January 12, 2026, Hyperfine reported preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025, highlighting a record fourth-quarter revenue of about $5.3 million, up 127% year-on-year and 54% sequent...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.